Robert Blum
speaker
321 appearances
1 recordings
1 series
first heard Feb 2026
last heard 3 Feb
Robert Blum’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Feb 2026 with 1.
Appearances
We've seen for having done exercise studies in cardiology before even Afikampton,
We understand a lot about how to pick the centers and how to make certain they're properly trained, whether or not they're using bicycle or treadmill.
These things matter and you have to be conscious of those as you're picking sites and picking investigators.
we are measuring our primary efficacy endpoint not at 24, but at 36.
But there are patients that stay on afterwards.
And we do believe that because we can get to target dose rapidly, and we demonstrated that with Redwood HCM cohort four, that patients are on their target dose with adequate exposure
to see the effects out to 36 weeks.
After that, there may be a plateauing of effect.
And that's echoed also in how we're conducting an open label extension called FOREST.
where we believe that data with OHCM are informative of NHCM.
And there we've presented data out to two years and we see where patient response can plateau.
So we think we've designed the right trial and duration
and time point to assess efficacy as we are doing in Acacia, but we'll know soon enough with data in Q2.
Yeah, so not sure I could say it's a brief history because this has been going on since 2005, 2006, when Omicampt and McCarville entered clinical trials and has been the subject of over 30 studies either we conducted or Amgen conducted when we were then in collaboration.
including a phase three study that Amgen conducted called Galactic that enrolled over 8,000 patients and was positive, P less than 0.05 for a hard clinical endpoint.
But it admittedly was modestly positive.
And the FDA asked us, because it wasn't less than 0.01, to do a confirmatory study.
We had sought to advise Amgen that based on our understandings of the mechanism of action in biology, that the treatment effect would be more pronounced in sicker patients with lower ejection fraction.
And we were right.
But we were unsuccessful in persuading Amgen to enroll patients with lower ejection fractions in that pivotal phase three study.
Showing 241–260 of 321 · page 13 of 17
← Previous
Next →